ClinConnect ClinConnect Logo
Search / Trial NCT06885918

ALS Research Collaborative

Launched by ALS THERAPY DEVELOPMENT INSTITUTE · Mar 13, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Arc Als Research Collaborative Als Tdi Als Therapy Develeopment Institute

ClinConnect Summary

The ALS Research Collaborative is a study aimed at understanding more about amyotrophic lateral sclerosis (ALS) and related conditions. Researchers want to gather information about how these diseases affect people, which can help in developing new treatments and finding better ways to measure how effective they are. This study is open to adults aged 18 and older who either have a diagnosis of ALS or another motor neuron disease, or who carry a known gene mutation linked to ALS. Healthy volunteers can also participate.

If you decide to join the study, you can provide information about your health and experiences either online or through other remote methods. The study is currently looking for participants, and it's important to note that you should be able to communicate in written English and not have significant cognitive impairment that would affect your ability to understand the study. Your participation could help advance research that may benefit many people living with ALS in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18 years of age or older
  • Can communicate in written English
  • Has a diagnosis of ALS/MND or is a known carrier of an ALS associated mutation
  • Exclusion Criteria:
  • Significant cognitive impairment that would prevent individual completion and understanding of the informed consent process.

About Als Therapy Development Institute

The ALS Therapy Development Institute (ALS TDI) is a leading nonprofit biotechnology organization dedicated to accelerating the development of effective treatments for amyotrophic lateral sclerosis (ALS). Founded by a team of scientists and advocates, ALS TDI focuses on rigorous preclinical research and innovative drug discovery methodologies to identify and advance promising therapeutic candidates. With a commitment to collaboration and transparency, the institute works closely with academic institutions, pharmaceutical companies, and the ALS community to foster groundbreaking research and ultimately improve the lives of those affected by this devastating disease. Through its comprehensive approach, ALS TDI strives to bring hope and tangible solutions to patients and families impacted by ALS.

Locations

Watertown, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Fernando G Vieira, M.D.

Principal Investigator

ALS Therapy Development Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported